Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users

Clinical Therapeutics
François LalibertéPatrick Lefebvre

Abstract

Compared with warfarin, the new target-specific oral anticoagulant agents may have advantages, such as shorter hospital length of stay, in patients with nonvalvular atrial fibrillation (NVAF). The objective of the present study was to assess, among patients with NVAF, the effects of rivaroxaban versus warfarin on the number of hospitalization days and other health care resource utilization in a cohort of rivaroxaban users and matched warfarin users. Data from health care claims dated from May 2011 to December 2012 from the Humana database were analyzed. Adult patients newly initiated on treatment with rivaroxaban or warfarin, with ≥2 diagnoses of AF (ICD-9-CM code 427.31), and without valvular AF were identified. Based on propensity score methods, warfarin recipients were matched 1:1 to rivaroxaban recipients. The end of the observation period was defined as the end of data availability, the end of insurance coverage, death, the date of a switch to another anticoagulant agent, or day 14 of treatment nonpersistence. The total number of hospitalization days and other health care resource utilization parameters (numbers of hospitalizations, emergency department [ED] visits, and outpatient visits) were evaluated using the method by...Continue Reading

References

Jan 1, 2010·The New England Journal of Medicine·Donald Stuart Houston, Ryan Zarychanski
May 5, 2011·Circulation. Cardiovascular Quality and Outcomes·Michael H KimKathy L Schulman
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Dec 15, 2012·Circulation·Alan S GoUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Jan 4, 2013·Circulation·Alan S GoUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Jan 10, 2013·Journal of Postgraduate Medicine·S Aditya
Jun 14, 2013·Current Atherosclerosis Reports·Graeme J Hankey, John W Eikelboom

❮ Previous
Next ❯

Citations

Jan 29, 2016·Expert Review of Pharmacoeconomics & Outcomes Research·Nicola Lucio Liberato, Monia Marchetti
Feb 20, 2018·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Lara M GroetzingerBelinda N Rivera-Lebron
Nov 22, 2018·American Journal of Therapeutics·Wilbert S Aronow, Tatyana A Shamliyan
Nov 17, 2015·Current Opinion in Cardiology·Christopher J Boos, Louise Brown
Apr 23, 2020·Journal of Population Therapeutics and Clinical Pharmacology Journal De La Thérapeutique Des Populations Et De La Pharamcologie Clinique·Anne HolbrookEleanor Pullenyegum
Aug 12, 2021·Journal of Comparative Effectiveness Research·François LalibertéJeffrey S Berger
Aug 28, 2021·Journal of Clinical Medicine·Ancuța Elena VîjanGheorghe-Andrei Dan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.